Indication
Real World Study
1 clinical trial
1 product
Clinical trial
Real World Study of Lolatinib for Patients With Advanced/Metastatic Anaplastic Lymphoma Kinase (ALK) - Positive Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2026-11-01
Product
Lorlatinib